As medications originally developed for diabetes become more widely used for weight management, clinicians face new questions about how these treatments may interact with established psychiatric medications.
One medication drawing attention is tirzepatide, sold under the brand names Zepbound and Mounjaro. In a new case report, a 50-year-old woman developed symptoms of lithium toxicity three weeks after adding tirzepatide. Her lithium level rose even though her dose and kidney function had not changed.
The report is the fourth published case of tirzepatide-associated lithium toxicity, its authors said. A single case can’t prove that tirzepatide is the cause of the problem, but the timing and the patient’s improvement after a lithium dose reduction have prompted calls for greater awareness.
The Results After Adding Tirzepatide
The patient had bipolar disorder, which they were taking lithium for. She had gradually moved to a 900-milligram nightly dose over a span of five weeks.
Before starting tirzepatide, her primary care laboratory tests showed normal kidney function, normal electrolyte levels, and a serum lithium level of 0.7 mmol/L.
Her mood stability improved, and she reported no adverse effects. She then began tirzepatide, which is sold as Zepbound. She received a 2.5-milligram injection once weekly for chronic weight management. Tirzepatide activates both GIP and GLP-1 receptors.
Three weeks later, she told her psychiatrist about blurred vision and reported a noticeable tremor in both hands along with slurred speech. The symptoms were new and had lasted two days. Her trough lithium level, measured the next day, had risen to 1.2 mmol/L.
She had not changed her lithium dose or how she took it, and she had started no other medications. Since beginning tirzepatide, she had been eating smaller meals, feeling full sooner, and experiencing bloating.
Symptoms Resolved After a Dose Reduction
Her care team advised reducing lithium to 450 milligrams nightly. As a result of the reduction of lithium, her symptoms soon subsided. A trough level taken 17 days later was 0.4 mmol/L.
The patient lost five pounds during her three weeks on tirzepatide. Due to the interaction risk, she and her doctor decided not to restart it. Her lithium dose was gradually returned to 900 milligrams nightly.
Jay Davis of the University of Colorado Anschutz Medical Campus and colleagues described the case in the Journal of Clinical Psychopharmacology.
Davis said the favored explanation involves increased fractional reabsorption associated with decreased food intake, but the interaction is still not well understood.
Mental Health Treatment and Medication Monitoring
Dr. Jorge Almeida, director of the bipolar disorder center at the University of Texas at Austin, reviewed the findings for MedPage Today and was not involved in the report.
He said it adds to a small but growing group of cases suggesting these medications may raise lithium levels, even when the dose is fixed and kidney function is normal.
“A single case can’t prove cause-and-effect, but the timeline and the resolution after the lithium dose was reduced make it hard to dismiss,” Almeida said.
He recommended early monitoring rather than automatically avoiding the medications, and said he would check lithium levels and kidney function within the first few weeks and again after dose changes.
Patients should also learn early warning signs of lithium toxicity, including the tremor, slurred speech, and blurred vision seen in this case. Almeida advised calling the prescriber rather than stopping either medication independently.
What Patients Should Know
People taking lithium can tell every prescriber about their full medication list and ask whether a new drug requires additional lab work. New neurological symptoms warrant prompt contact with the prescribing clinician.
The report’s authors described lithium as a cornerstone of bipolar disorder management despite its limitations, while also recognizing the potential benefits of incretin medications for type 2 diabetes and obesity.
Finding The Right Treatment Support
Ask how programs manage psychiatric medications and communicate with primary care providers. Medication monitoring, laboratory follow-up and clear instructions for new symptoms are useful parts of a care plan.
Rehab.com’s directory can help you compare mental health and addiction treatment programs. Call
800-985-8516
( 
Sponsored Helpline )
to speak with a treatment advisor about available options.
